Literature DB >> 20633008

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

K Abuabara1, R S Azfar, D B Shin, A L Neimann, A B Troxel, J M Gelfand.   

Abstract

BACKGROUND: Severe psoriasis is associated with excess mortality and increased risk of cardiovascular death. Population-based data evaluating cause-specific mortality in patients with psoriasis are limited.
OBJECTIVES: To describe cause-specific mortality in patients with severe psoriasis.
METHODS: We performed a cohort study from 1987 to 2002 of patients ≥18 years using the General Practice Research Database. We compared patients with a psoriasis code and a history of systemic therapy consistent with severe psoriasis (n=3603) with patients with no history of psoriasis (n=14,330). Age- and sex-adjusted Cox models were created for each of the leading causes of death defined by the Centers for Disease Control.
RESULTS: Patients with severe psoriasis were at increased risk of death from cardiovascular disease [hazard ratio (HR) 1·57, 95% confidence interval (CI) 1·26-1·96], malignancies (HR 1·41, 95% CI 1·07-1·86), chronic lower respiratory disease (HR 2·08, 95% CI 1·24-3·48), diabetes (HR 2·86, 95% CI 1·08-7·59), dementia (HR 3·64, 95% CI 1·36-9·72), infection (HR 1·65, 95% CI 1·26-2·18), kidney disease (HR 4·37, 95% CI 2·24-8·53) and unknown/missing causes (HR 1·43, 95% CI 1·09-1·89). The absolute and excess risk of death was highest for cardiovascular disease (61·9 and 3·5 deaths per 1000 patient-years, respectively).
CONCLUSIONS: Severe psoriasis is associated with an increased risk of death from a variety of causes, with cardiovascular death being the most common aetiology. These patients were also at increased risk of death from causes not previously reported, such as infection, kidney disease and dementia. Additional studies are necessary to determine the degree to which excess causes of death are due to psoriasis, its treatments, associated behaviours, or other factors. © The Authors. BJD
© 2010 British Journal of Dermatology.

Entities:  

Mesh:

Year:  2010        PMID: 20633008      PMCID: PMC2966545          DOI: 10.1111/j.1365-2133.2010.09941.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  57 in total

Review 1.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

Review 2.  Comorbidities in patients with psoriasis.

Authors:  Alice B Gottlieb; Frank Dann
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

Review 3.  Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.

Authors:  Sarah T Pendlebury; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2009-09-24       Impact factor: 44.182

4.  Psoriasis and risk of incident myocardial infarction, stroke or transient ischaemic attack: an inception cohort study with a nested case-control analysis.

Authors:  Y B Brauchli; S S Jick; M Miret; C R Meier
Journal:  Br J Dermatol       Date:  2009-02-04       Impact factor: 9.302

Review 5.  Hypertension and dementia.

Authors:  Michiaki Nagai; Satoshi Hoshide; Kazuomi Kario
Journal:  Am J Hypertens       Date:  2009-11-19       Impact factor: 2.689

6.  The risk of stroke in patients with psoriasis.

Authors:  Joel M Gelfand; Erica D Dommasch; Daniel B Shin; Rahat S Azfar; Shanu K Kurd; Xingmei Wang; Andrea B Troxel
Journal:  J Invest Dermatol       Date:  2009-05-21       Impact factor: 8.551

Review 7.  Risk factors for dementia.

Authors:  Jen-Hau Chen; Kun-Pei Lin; Yen-Ching Chen
Journal:  J Formos Med Assoc       Date:  2009-10       Impact factor: 3.282

Review 8.  Depression and quality of life in psoriasis.

Authors:  Abby S Van Voorhees; Richard Fried
Journal:  Postgrad Med       Date:  2009-07       Impact factor: 3.840

9.  The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.

Authors:  Shanu Kohli Kurd; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2008-11-20       Impact factor: 11.527

Review 10.  Validation and validity of diagnoses in the General Practice Research Database: a systematic review.

Authors:  Emily Herrett; Sara L Thomas; W Marieke Schoonen; Liam Smeeth; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

View more
  118 in total

1.  Validity of The Health Improvement Network (THIN) for the study of psoriasis.

Authors:  N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand
Journal:  Br J Dermatol       Date:  2011-02-03       Impact factor: 9.302

2.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

3.  Psoriasis and cardiovascular risk: strength in numbers, part II.

Authors:  Joel M Gelfand; Nehal N Mehta; Sinéad M Langan
Journal:  J Invest Dermatol       Date:  2011-05       Impact factor: 8.551

4.  Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer.

Authors:  Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2018-04-03       Impact factor: 11.527

5.  Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis.

Authors:  Alexis Ogdie; Samantha Maliha; Daniel Shin; Thorvardur Jon Love; Joshua Baker; Yihui Jiang; Hyon Choi; Joel M Gelfand
Journal:  Rheumatology (Oxford)       Date:  2017-06-01       Impact factor: 7.580

Review 6.  The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Erica D Dommasch; Katrina Abuabara; Daniel B Shin; Josephine Nguyen; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2011-02-18       Impact factor: 11.527

Review 7.  In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.

Authors:  Sarah A R Siegel; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2019-06-06       Impact factor: 4.592

8.  Psoriasis and Risk of Mental Disorders in Denmark.

Authors:  Michelle Z Leisner; Jette L Riis; Sara Schwartz; Lars Iversen; Søren D Østergaard; Morten S Olsen
Journal:  JAMA Dermatol       Date:  2019-06-01       Impact factor: 10.282

Review 9.  Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs.

Authors:  Akhil Sood; Mukaila A Raji
Journal:  Clin Rheumatol       Date:  2020-08-30       Impact factor: 2.980

10.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.